Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

NCT07542496 is registered in ClinicalTrials.gov with Société Algérienne de Formation et Recherche en Oncologie as lead sponsor.

NCT NCT07542496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07542496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
Lead sponsor
Société Algérienne de Formation et Recherche en Oncologie
Phase
Observational
Overall status
Recruiting
Start date
January 15, 2026
Completion date
January 15, 2027
Enrollment
1,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her 2 positive breast cancer